-
Biomarin limits marketing of its FVIII gene therapy, Roctavian
SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy valoctocogene roxaparvovec (Roctavian) to...
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
Contributing to the advancement of scientific knowledge
PREAMBLE We have already come to the end of this important series of articles about the national board and operational committees on which our volunteers sit. On this occasion,...
Don’t ever turn your back on your dreams!
My name is Andrea, and I am the mom to my son Nicklas, who has severe hemophilia A. I am writing today to share a truly heartwarming success story...
